2020 Anti-Doping Testing Figures / World Anti-Doping Agency (WADA). - Montreal : WADA, 2021

Contents:

• Executive Summary - pp. 2-9 (7 pages)
• Laboratory Report -– pp. 10-36 (27 pages)
• Sport Report - pp. 37-137 (101 pages)
• Testing Authority Report - pp. 138-244 (107 pages)
• ABP Report-Blood Analysis - pp. 245-279 (35 pages)

Report Highlights:

• A 46% decrease in the overall number of samples analyzed: 278,047 in 2019 to 149,758 in 2020.
• A decrease in the total percentage of Adverse Analytical Findings (AAFs): 0.97% in 2019 (2,702 AAFs from 278,047 samples) to 0.67% in 2020 (1,009 AAFs from 149,758 samples).
• All WADA-accredited Laboratories saw a decrease in the total number of samples recorded.
• A decrease in the total number and percentage of non-Athlete Biological Passport (ABP) blood samples analyzed: 9.1% in 2019 (25,339 of 278,047) and 7.3% (10,940 of 149,758) in 2020.
• A decrease of 38% in the number of ABP blood samples tested: 36,401 in 2019 to 22,666 in 2020.

The World Anti-Doping Agency (WADA) has publishes its 2020 Testing Figures Report (2020 Report), which summarizes the results of all the samples WADA-accredited Laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2020.

This is the sixth and last set of global testing figures under the 2015 World Anti-Doping Code (Code) that came into effect in January 2015. The 2020 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples; blood and ABP blood data; and, the resulting Adverse Analytical Findings (AAFs) and Atypical Findings (ATFs).

2021 Anti-Doping Testing Figures / World Anti-Doping Agency (WADA). - Montreal : WADA, 2023

Contents:

• Executive Summary - pp. 2-9 (7 pages)
• Laboratory Report -– pp. 10-39 (30 pages)
• Sport Report - pp. 40-153 (114 pages)
• Testing Authority Report - pp. 154-267 (114 pages)
• ABP Report-Blood Analysis - pp. 268-311 (44 pages)

Report Highlights:

• A 61.2% increase in the number of samples (both urine and non-ABP blood samples) analyzed
  and reported into ADAMS: 149,758 in 2020 to 241,430 in 2021.
• An increase in the total number of samples analyzed and reported by nearly all WADAaccredited
  laboratories and WADA-approved laboratories into ADAMS in 2021 compared to 2020.
• An increase in the total number and percentage of non-ABP blood samples analyzed: 7.3%
  (10,940 of 149,758 samples) in 2020 to 9.3% (22,398 Blood + DBS samples out of 241,430).
• An increase of 36% in the number of ABP blood samples analyzed: 22,666 in 2020 to 30,821
  in 2021.
• A decrease in the total percentage of AAFs: 0.67% in 2020 (1,009 AAFs from 149,758
  samples) to 0.65% (1,560 AAFs from 241,430 samples).
• An increase in the total number of AAFs for growth hormone (GH): 1 in 2020 to 7 in 2021,
  including the first reported AAF for a GH biomarker.
• A 46% decrease in the overall number of samples analyzed: 278,047 in 2019 to 149,758 in 2020.
• A decrease in the total percentage of Adverse Analytical Findings (AAFs): 0.97% in 2019 (2,702 AAFs from 278,047 samples) to 0.67% in 2020 (1,009 AAFs from 149,758 samples).
• All WADA-accredited Laboratories saw a decrease in the total number of samples recorded.
• A decrease in the total number and percentage of non-Athlete Biological Passport (ABP) blood samples analyzed: 9.1% in 2019 (25,339 of 278,047) and 7.3% (10,940 of 149,758) in 2020.
• A decrease of 38% in the number of ABP blood samples tested: 36,401 in 2019 to 22,666 in 2020.

The World Anti-Doping Agency (WADA) has publishes its 2021 Testing Figures Report (2021 Report), which summarizes the results of all the samples WADA-accredited laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2021.

This is the first set of global testing figures under the 2021 World Anti-Doping Code (Code) that came into effect in January 2021. The 2021 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples, blood and ABP blood data, and the resulting Adverse Analytical Findings (AAFs) and Atypical Findings (ATFs).

2022 Anti-Doping Testing Figures / World Anti-Doping Agency (WADA). - Montreal : WADA, 2024

Contents:

• Executive Summary - pp. 2-9 (7 pages)
• Laboratory Report - pp. 10-39 (30 pages)
• Sport Report - pp. 40-155 (116 pages)
• Testing Authority Report - pp. 156-279 (124 pages)
• ABP Report-Blood Analysis - pp. 280-320 (41 pages)

Report Highlights:

• A 6.4% increase in the total number of samples (including urine, non-ABP blood and dried blood spot samples) analyzed and reported into ADAMS in 2022 (256,770) vs. 2021 (241,430); 

• An increase in the total percentage of AAFs year on year; 

• An increase in the total number of samples analyzed and reported by most WADA-accredited laboratories and WADA-approved laboratories into ADAMS in 2022 vs 2021. 

• An increase in the total number and percentage of non-ABP blood and DBS samples analyzed in 2022.  

• An increase of 1.4% in the number of ABP blood samples analyzed in 2022. 

• An increase in the total number of AAFs and % AAF for ERAs [including erythropoietin (EPO) and other EPO-receptor agonists], GHRFs and GC/C/IRMS tests in 2022.  

The World Anti-Doping Agency (WADA) has published its 2022 Testing Figures Report (2022 Report), which summarizes the results of all the samples WADA-accredited laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2022. 

The 2022 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples, blood and ABP blood data, and the resulting Adverse Analytical Findings (AAFs) and Atypical Findings (ATFs). 

WADA Independent Observer Mission Report 16th Asian Games Guangzhou, China November 2010 / Independent Observer Team. - Montreal : World Anti-Doping Agency (WADA), 2010

Report of the Independent Observers XVIII Asian Games Jakarta Palembang 2018 / Independent Observer Team. - Montreal : World Anti-Doping Agency (WADA), 2019

Report of the Independent Observers 19th Asian Games
Hangzhou, China 2022 / Independent Observer Team. - Montreal : World Anti-Doping Agency (WADA), 2024

WADA Independent Observer Report Olympic Games 2000 Sydney, Australia / Harri Syväsalmi. - Independent Observer Team. - World Anti-Doping Agency (WADA), 2000

Contents:

- Introduction
- Laboratory
- Doping Control Command Centre
- Doping Control Stations
- Doping Control Officers
- Doping Control Procedures
- Courier
- Recommendations
- Annex 1. Medical Report
- Annex 2. Laboratory Report
- Annex 3. Result Management
- Appendices:
- IO Terms of Reference
- Confidentiality Document
- Conflict of Interest Doc
- IO Team
- Observation Summary

World Anti-Doping Agency Independent Observer Report Olympic Summer Games 2004 Athens / Ulrich Haas. - Independent Observer Team. - Montreal : World Anti-Doping Agency (WADA), 2004